Qingdao oncology-focused healthcare group, controlled by Haier, running cancer hospitals and making gamma-knife radiotherapy equipment.
Qingdao oncology-focused healthcare group, controlled by Haier, running cancer hospitals and making gamma-knife radiotherapy equipment.
Earns most of its income from running hospitals, mainly cancer-focused ones in Sichuan and Suzhou, paid by patients and insurers, with a smaller line selling Masep gamma knives and radiotherapy machines to other hospitals. Haier Group took control in 2019 and built the hospital business on top of the gamma-knife maker it inherited.
Moat: narrow (regulatory licence, installed base). Licensed hospital network and a gamma-knife installed base; both are fragmented, local markets.
Headquarters: Qingdao, China · Founded: 1998 · Employees: 2,662
Size INKON Life Technology (300143.SZ) is a China Health Care company (Medical Specialties) with a market value of $985M, the 2181st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.86 on 18 Nov 2026.
Performance Over six months the shares fell 23.1%, against -7.3% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 22.0% over the last twelve months (peer median +10.6%); the operating margin is 11.8% (peer median 8.9%).
Valuation It trades at 50.3× forward earnings against a peer median of 19.3× (3rd most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.8 points above its cost of capital (8.4% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.06B | CN¥1.88B | CN¥1.56B | CN¥1.47B | CN¥1.16B |
| Revenue growth | — | +21% | +6% | +27% | — |
| Gross profit | CN¥647M | CN¥476M | CN¥372M | CN¥389M | CN¥294M |
| EBITDA | n/a | CN¥321M | CN¥216M | CN¥225M | CN¥169M |
| Net income | CN¥83.7M | CN¥68.5M | CN¥115M | CN¥100M | -CN¥596M |
| Free cash flow | CN¥339M | CN¥114M | CN¥60.6M | CN¥31.8M | CN¥35.3M |
| Capital expenditure | CN¥156M | CN¥227M | CN¥199M | CN¥158M | CN¥125M |
| Total debt | CN¥805M | CN¥763M | CN¥336M | CN¥299M | CN¥115M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| INKON Life Technology 300143.SZ | $985M | -23% | +22% | 12% | 50.3× | 10.7% |
| Hygeia Healthcare 6078.HK | $811M | -3% | +2% | 14% | 10.4× | 4.6% |
| Elekta EKTA-B.ST | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% |
| Accuray ARAY | n/a | -81% | n/a | n/a | n/a | n/a |
| Siemens Healthineers SHL.DE | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300143.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.9% | +0.9% | 4th lowest of 21 |
| 6-month return | -23.1% | -7.3% | 4th lowest of 21 |
| Distance from 52-week high | -38.0% | -27.5% | 6th lowest of 21 |
| Revenue growth (TTM) | +22.0% | +10.6% | 4th highest of 21 |
| Operating margin | 11.8% | 8.9% | 8th highest of 21 |
| Forward P/E | 50.3× | 19.3× | 3rd most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 10.7% | 6.9% | 5th most demanding of 14 |
| Growth delivered (Del g) | +12.9% | +10.4% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -2.2 pp | -3.0 pp | 7th most demanding of 14 |
| ROIC minus cost of capital | +2.8 pp | +0.3 pp | 10th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 18.7× | -6.1% | +11.7% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 15.8× | 1.3% | +4.7% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 20.9× | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | n/a | 32.6% | +21.0% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 70.5× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 383.6× | n/a | n/a |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |